Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, intra alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Abstract: GPR174 is an orphan receptor that has been implicated in cancer, nervous system diseases and disorders and neuroregeneration. We have identified inhibitors of GPR174 and have identified the G-protein signaling pathways that GPR174 modulates. Based on this discovery, the present invention features methods for inhibiting GPR174 activity and thereby stimulating an immune response in a subject in need thereof, particularly in the use of treatment of non-malignant neoplasms, malignant neoplasms (i.e., cancer), nervous system diseases and disorders and neuroregeneration, as well as related compositions.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

Abstract: GPR174 is an orphan receptor that has been implicated in cancer, nervous system diseases and disorders and neuroregeneration. We have identified inhibitors of GPR174 and have identified the G-protein signaling pathways that GPR174 modulates. Based on this discovery, the present invention features methods for inhibiting GPR174 activity and thereby stimulating an immune response in a subject in need thereof, particularly in the use of treatment of non-malignant neoplasms, malignant neoplasms (i.e., cancer), nervous system diseases and disorders and neuroregeneration, as well as related compositions.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Abstract: This disclosure describes methods and compositions for measuring the binding specificity, kinetics and affinity of kinase inhibitors indirectly using mass sensing analytical techniques, such as SPR, through the competitive displacement of detectable signal-inducing kinase binding molecule. Further provided are methods for preparing such molecules.

Abstract: This disclosure describes methods and compositions for measuring the binding specificity, kinetics and affinity of kinase inhibitors indirectly using mass sensing analytical techniques, such as SPR, through the competitive displacement of detectable signal-inducing kinase binding molecule. Further provided are methods for preparing such molecules.

Abstract: This disclosure describes methods and compositions for measuring the binding specificity, kinetics and affinity of kinase inhibitors indirectly using mass sensing analytical techniques, such as SPR, through the competitive displacement of detectable signal-inducing kinase binding molecule. Further provided are methods for preparing such molecules.

Abstract: According to an embodiment, an SPR analysis system includes an SPR analysis system control computer program having a graphical user interface and configured to control the operation of an SPR analysis apparatus. According to an embodiment, an SPR data analysis computer program includes an SPR microarray video viewer and a sensorgram generator responsive to the SPR video.

Abstract: According to an embodiment, an SPR analysis system includes a housing enclosing with a fluid supply volume substantially enclosed within the housing, a flow cell module configured to receive reagents and analyte from the fluid supply volume, and an enclosed optics assembly configured to interrogate a microarray portion of the flow cell module.